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ABSTRACT
Parkinson disease (PD)-affected brains show consistent endoplasmic reticulum (ER) stress and mito-
phagic dysfunctions. The mechanisms underlying these perturbations and how they are directly 
linked remain a matter of questions. XBP1 is a transcription factor activated upon ER stress after 
unconventional splicing by the nuclease ERN1/IREα thereby yielding XBP1s, whereas PINK1 is a kinase 
considered as the sensor of mitochondrial physiology and a master gatekeeper of mitophagy 
process. We showed that XBP1s transactivates PINK1 in human cells, primary cultured neurons and 
mice brain, and triggered a pro-mitophagic phenotype that was fully dependent of endogenous 
PINK1. We also unraveled a PINK1-dependent phosphorylation of XBP1s that conditioned its nuclear 
localization and thereby, governed its transcriptional activity. PINK1-induced XBP1s phosphorylation 
occurred at residues reminiscent of, and correlated to, those phosphorylated in substantia nigra of 
sporadic PD-affected brains. Overall, our study delineated a functional loop between XBP1s and 
PINK1 governing mitophagy that was disrupted in PD condition.
Abbreviations: 6OHDA: 6-hydroxydopamine; baf: bafilomycin A1; BECN1: beclin 1; CALCOCO2/ 
NDP52: calcium binding and coiled-coil domain 2; CASP3: caspase 3; CCCP: carbonyl cyanide 
chlorophenylhydrazone; COX8A: cytochrome c oxidase subunit 8A; DDIT3/CHOP: DNA damage 
inducible transcript 3; EGFP: enhanced green fluorescent protein; ER: endoplasmic reticulum; ERN1/ 
IRE1α: endoplasmic reticulum to nucleus signaling 1; FACS: fluorescence-activated cell sorting; 
HSPD1/HSP60: heat shock protein family D (Hsp60) member 1; MAP1LC3/LC3: microtubule associated 
protein 1 light chain 3; MFN2: mitofusin 2; OPTN: optineurin; PD: Parkinson disease; PINK1: PTEN- 
induced kinase 1; PCR: polymerase chain reaction:; PRKN: parkin RBR E3 ubiquitin protein ligase; 
XBP1s [p-S61A]: XBP1s phosphorylated at serine 61; XBP1s [p-T48A]: XBP1s phosphorylated at 
threonine 48; shRNA: short hairpin RNA, SQSTM1/p62: sequestosome 1; TIMM23: translocase of 
inner mitochondrial membrane 23; TM: tunicamycin; TMRM: tetramethyl rhodamine methylester; 
TOMM20: translocase of outer mitochondrial membrane 20; Toy: toyocamycin; TP: thapsigargin; UB: 
ubiquitin; UB (S65): ubiquitin phosphorylated at serine 65; UPR: unfolded protein response, XBP1: 
X-box binding protein 1; XBP1s: spliced X-box binding protein 1
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Introduction
Parkinson disease (PD) is a movement disorder characterized 
by the degeneration of dopaminergic neurons. Various cellu-
lar dysfunctions including altered dopamine metabolism, 
increased oxidative stress, mitochondrial failure, altered cal-
cium homeostasis, neuroinflammation, impaired autophagy 
and proteasome dysfunctions appear tightly linked to PD- 
associated neuronal loss [1]. Furthermore, numerous evidence 
indicate that the intracellular accumulation of misfolded pro-
teins notably SNCA/alpha-synuclein [2,3] and endoplasmic 
reticulum (ER) overload could contribute to this pathology 
[1,4,5]. The ER overload-associated stress leads to the activa-
tion of the unfolded protein response (UPR). The UPR con-
sists of a coordinated signaling response tailored to the stress 
severity that will either restore ER homeostasis and preserve 
the cell or trigger its elimination by apoptosis in case of 
exacerbated stress. The UPR response is elicited by three 
stress sensors located at the ER membrane, namely, 
EIF2AK3/PERK (eukaryotic translation initiation factor 2 
alpha kinase 3), ATF6 (activating transcription factor 6) and 
ERN1/IRE1α (endoplasmic reticulum to nucleus signaling 1) 
[6,7]. Importantly, postmortem studies of PD-affected human 
brains [8–11] as well as toxin-induced [12–14] and genetically 
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designed cellular and animal models of PD converge to point 
to the key role of the UPR in PD [4,15].
ERN1 is the most evolutionary conserved ER stress trans-
ducer of the UPR that harbors a kinase and RNAse activity 
[16]. ERN1-mediated signaling is a positive regulator of cell 
survival that stops upon beyond repair ER stress resulting in 
apoptosis. It is responsible for the unconventional splicing of 
XBP1 (X box binding protein 1) [15–17] yielding its tran-
scriptionally active form XBP1s (XBP1 spliced). XBP1s regu-
lates genes involved in protein folding and ER-associated 
degradation (ERAD) and is frequently associated with a pro- 
survival phenotype in dopaminergic neurons [18–20]. 
Interestingly, XBP1s was shown to participate in the macro-
autophagy/autophagy-mediated degradation process [21,22]. 
The molecular mechanisms underlying this control remain 
poorly understood. It should be noted that specialized elim-
ination of dysfunctional mitochondria by mitophagy requires 
the recruitment of PRKN/parkin by PINK1 (PTEN induced 
kinase 1), a kinase that is considered as the cellular sensor of 
mitochondrial health [23]. Noteworthy, PRKN has been 
shown to control XBP1s transcription [24] and to promote 
PSEN (presenilin)-dependent control of PINK1 [25]. Thus, we 
questioned whether XBP1s could be directly involved in the 
control of mitophagy and whether such phenotype could 
involve a PINK1-dependent process. Our work demonstrated 
that XBP1s controlled mitophagy via the transcriptional reg-
ulation of PINK1 in various cellular models as well as in vivo. 
Interestingly, we established that XBP1s underwent PINK1- 
dependent phosphorylation at sites reminiscent of those 
hyperphosphorylated in sporadic PD-affected substantia 
nigra. This was the first demonstration of a direct role of 
XBP1s transcriptional factor function in the control of mito-
phagy and the occurrence of a functional XBP1s-PINK1 loop 
governing mitophagy that could be disrupted in pathological 
conditions.
Results
Stress activators and ERN1 blockers similarly affect XBP1s 
and PINK1 in dopaminergic and primary cultured neurons 
as well as in mice brain
In SH-SY5Y dopaminergic neurons, the ER stress inducer 
thapsigargin (TP) similarly increased XBP1s and PINK1 pro-
tein expressions in a time-dependent manner (Fig. S1A and 
S1B). Accordingly, 8 h of TP treatment enhanced PINK1 
promoter activity (Fig. S1C) and mRNA levels (Fig. S1D). 
We have chosen a treatment with TP for 8 h because it 
corresponded to the optimal time of induction for both 
PINK1 and XBP1s protein levels. It should be noted that in 
our experimental setting, after 8 h of TP treatment, SH-SY5Y 
cells were already committed to apoptotic program as illu-
strated by the increased expression of the ER stress-induced 
protein DDIT3/CHOP (DNA damage inducible transcript 3) 
(Fig. S1A). We examined whether ER stress-mediated 
enhancement of PINK1 transcriptional regulation could well 
be triggered by XBP1s. In order to address this question, we 
used toyocamycin (Toy), a specific blocker of ERN1 that is 
responsible for XBP1s functional activation after XBP1 
splicing [26] and that displays few nonspecific effects on 
several other kinases [27–29]. As expected, Toy fully pre-
vented the TP-induced increase of XBP1s expression (Figure 
1A). Interestingly, Toy also reduced the basal protein (Figure 
1A) and mRNA (Figure 1B) expressions of PINK1 but also 
fully blocked their TP-induced increases (Figure 1A, B). It 
should be noted that this data could indicate that even in basal 
non-stimulated condition, there exists a low but functional 
XBP1s production (poorly detectable by western blot but that 
can be unraveled upon long gel exposures) as we previously 
established by mRNA splicing analysis [24] that is prevented 
by Toy. Importantly, in order to rule out any bias linked to 
cell immortalization, we examined the influence of TP and 
another ER stress modulator tunicamycin (TM) on XBP1s 
and PINK1 regulation in rat primary cultured neurons. Both 
TP (Fig. S2A-C) and TM (Fig. S2D-F), enhanced XBP1s (Fig. 
S2A and S2D) and PINK1 (Fig. S2A, S2B, S2D, and S2E) 
protein expressions and Pink1 mRNA levels (Fig. S2C and 
S2F). Of importance, TM also increased XBP1s (Fig. S2G) and 
PINK1 (Fig. S2G and S2H) protein expressions and Pink1 
mRNA levels (Fig. S2I) in 2-month-old treated wild-type 
mice.
XBP1s modulates PINK1 expression at a transcriptional 
level
Next, we examined the impact of XBP1s on PINK1 regulation 
by a genetic approach. We demonstrated that Xbp1s transient 
overexpression (see expression of XBP1s in Figure 1C, upper 
panel) increased PINK1 protein expression (Figure 1C) 
mRNA levels (Figure 1E) and promoter transactivation 
(Figure 1D). It should be noted that in agreement with its pro- 
mitophagic role, XBP1s overexpression (Fig. S3A and S3C) 
led to an accumulation of PINK1 in the TIMM23 (translocase 
of inner mitochondrial membrane 23)-positive mitochondria- 
enriched compartment (Fig. S3A and S3B) similarly to control 
carbonyl cyanide m-chlorophenylhydrazone (CCCP) treat-
ment known to stabilize PINK1 protein at the outer mito-
chondrial membrane. In order to confirm these data at an 
endogenous level, we examined the regulation of endogenous 
PINK1 in SH-SY5Y stably infected with lentiviral construct 
harboring a short hairpin RNA (shRNA) targeting XBP1. Fig. 
S4 showed infection efficacy by means of GFP imaging (Fig. 
S4A) that was correlated with a drastic reduction of XBP1s 
protein expression (Fig. S4B) and a 54% reduction in XBP1s 
mRNA levels (Fig. S4C). Genetic downregulation of XBP1 led 
to drastic reductions of PINK1 protein expression (Figure 1F), 
mRNA levels (Figure 1H) and promoter transactivation 
(Figure 1G). Interestingly, in primary cultured neurons, 
XBP1s overexpression (Fig. S5A-C) increased PINK1 protein 
expression (Fig. S5A), mRNA levels (Fig. S5C) and promoter 
activity (Fig. S5B) while conversely, Xbp1 knockdown (Xbp1 
KD) (Fig. S5D-F) lowered PINK1 protein (Fig. S5D) and 
mRNA (Fig. S5F) expressions. XBP1s protein overexpression 
and mRNA depletion levels are illustrated in Fig. S5A and 
S5E, respectively. Moreover, we examined the influence of 
XBP1 depletion on PINK1 expression in differentiated dopa-
minergic SH-SY5Y cells (Fig. S5G). The efficacy of dopami-
nergic differentiation by retinoic acid and phorbol ester 
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Figure 1. ER stress modulators and XBP1s regulate PINK1 transcription. (A and B) SH-SY5Y cells were treated for 8 h with vehicle (Ct, DMSO), toyocamycin (Toy, 1 µM), 
thapsigargin (TP, 1 µM) or thapsigargin and toyocamycin (TP/Toy). In TP/Toy condition, cells were pretreated for 16 h with Toy then TP was added for 8 h. Then, 
PINK1 and XBP1s protein expressions (A, N = 12, One-way ANOVA, Tukey’s multiple comparisons test) and PINK1 mRNA levels (B, N = 9, One-way ANOVA, Tukey’s 
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subsequent treatment was illustrated by the increased level of 
the canonical dopaminergic marker, tyrosine hydroxylase 
(TH). We showed that, as we observed in non-differentiated 
SH-SY5Y cells, the depletion of endogenous XBP1 led to 
decreased PINK1 protein levels in SH-SY5Y differentiated 
cells. The above set of data confirmed the ability of endogen-
ous and overexpressed XBP1s to upregulate PINK1 in both 
dopaminergic, primary cultured neurons as well as in differ-
entiated dopaminergic SH-SY5Y cells.
The fact that XBP1s is a transcription factor and that 
PINK1 mRNA levels were modulated led us to examine 
whether XBP1s could act as a direct activator of Pink1 tran-
scription. Interestingly, in silico analysis of Pink1 promoter 
region identified two putative XBP1s responsive elements 
(Figure 1I, black boxes in P2.0 construct). We carried out 5ʹ 
end deletion experiments of the full-length Pink1 promoter in 
frame with a luciferase gene reporter. First, we confirmed that 
Xbp1s expression (Figure 1J, upper panel) dramatically 
enhanced the transactivation of full-length Pink1 promoter 
(Figure 1J, P2.0). Truncation of the region harboring the 
most 5ʹ end responsive element (−2054/-2049, see Figure 1I, 
construct P1.3) did not affect the XBP1s-mediated transacti-
vation of the Pink1 promoter construct (Figure 1J). 
Conversely, the deletion of the −1354/-854 region harboring 
the second responsive element (−1026/-1021, see Figure 1I 
construct P0.8) abolished the XBP1s-mediated Pink1 transac-
tivation (Figure 1J). This was supported by the examination of 
the P0.4 construct (Figure 1I, J). We confirmed the function-
ality of this responsive element by site-directed deletion. We 
showed that partial removal of this responsive element 
(−1024/-1021) yielded a construct (P2.0∆, Figure 1K left 
panel) that remained unresponsive to XBP1s (Figure 1K, 
right panel).
The direct interaction of XBP1s with PINK1 promoter was 
further demonstrated by gel shift analysis. In this experiment, 
recombinant XBP1s was incubated with biotinylated Pink1 
probes encompassing the delineated functional 1025–1021 
domain of Pink1 promoter. This bimolecular in vitro interac-
tion allowed unraveling a direct physical interaction without 
the participation of any additional transcriptional cofactor. 
Figure 1L showed that, indeed, XBP1s interacted with Pink1 
probe (Figure 1L compare lane 1 and 2), a label abolished by 
an excess of unlabeled probe (Figure 1L, compare lanes 2 
and 3). Overall, this set of data indicated that XBP1s acted 
as a direct transcriptional activator of Pink1 gene and identi-
fied the responsive element mediating XBP1s-Pink1 promoter 
functional interaction.
XBP1s modulates mitophagy and mitochondrial health
We assessed the functional influence of XBP1s expression on 
mitochondrial physiology and mitophagy, two processes 
tightly controlled by PINK1. This was assessed by monitoring 
a panel of autophagy/mitophagy protein reporters, some of 
which were previously shown to be linked to PINK1 [30,31]. 
We measured: 1) the expression of BECN1 (beclin 1) that is 
a pro-autophagy protein implicated in autophagosome forma-
tion and maturation [32]; 2) the ratio of MAP1LC3-II/LC3-II 
(lipidated microtubule associated protein 1 light chain 3) vs. 
LC3-I expression, the modulation of which reflects autopha-
gosome formation [33]; 3) SQSTM1/p62 (sequestosome 1), 
OPTN (optineurin) and CALCOCO2/NDP52 levels that are 
autophagic receptors that have been linked to PRKN-PINK1 
mitophagy process [34]; 4) the expressions of TOMM20, 
TIMM23 and HSPD1/HSP60 (heat shock protein mitochon-
drial chaperone located at the mitochondrial matrix) that are 
biochemical markers of mitochondrial mass classically used to 
follow early and late mitophagic processes; 5) the levels of 
ubiquitin phosphorylated at serine 65 (UB [S65]) and PRKN, 
two substrates of PINK1 involved in the control of mito-
phagy [33].
First, we assessed the impact of XBP1s on autophagic flux. 
Xbp1s cDNA transfection led to an increased LC3-II:LC3-I 
ratio (Figure 2A, B) and reduced SQSTM1 (Figure 2A, C) 
expression. Importantly, bafilomycin A1 (baf), which is classi-
cally used to trigger autolysosome acidification and to disrupt 
autophagosome-lysosome fusion [33], increased XBP1s- 
mediated modulations of LC3-II:LC3-I and SQSTM1 (Figure 
2A, C) thereby confirming that XBP1s increased autophagic/ 
mitophagic flux. Next, we showed that Xbp1s transient 
multiple comparisons test) were analyzed as described in Materials and Methods. Data are expressed as percent of control DMSO-treated cells (taken as 100%) and 
are the means ± SEM of 3–4 independent experiments performed in triplicates. GAPDH expression (A) is provided as a control of protein load. (C-E) SH-SY5Y cells 
were transiently transfected with an empty pcDNA3 vector (Ev) or wild-type Xbp1s cDNA. Twenty-four hours after transfection, PINK1 protein expression (C, N = 12, 
analyzed by Student’s t test), promoter transactivation (D, N = 15, Student’s t test) and mRNA levels (E, N = 12, Student’s t test) were analyzed as described in 
Materials and Methods. SH-SY5Y cells treated with CCCP (CP, 10 µM for 6 h) were included as migration controls for PINK1. Data are expressed as percent of control 
Ev-transfected cells (taken as 100%) and are the means ± SEM of 4–5 independent experiments performed in triplicates. ACTB and XBP1s expressions are provided in 
(C) as a control of protein load and Xbp1s transfection efficiency. (F-H) SH-SY5Y stably expressing scrambled (SC) or shRNA-targeting XBP1 (XBP1 KD) were assessed for 
PINK1 protein expression (F, N = 9, analyzed by Student’s t test), PINK1 promoter transactivation (G, N = 15, Student’s t test) and PINK1 mRNA levels (H, N = 18, 
Student’s t test) as described in Methods. Data are expressed as percent of control SC cells (taken as 100%) and are the means ± SEM of 3–6 independent 
experiments performed in triplicates. ACTB expression is provided in (F) as a control of protein load. (I) The scheme represents the full-length (FL, P2.0) mouse Pink1 
promoter region and 5ʹ end deletion constructs (P1.3, P0.8 and P0.4) in frame with luciferase. Black boxes on P2.0 construct correspond to two putative Xbp1s 
responsive elements. (J) Promoter constructs were then co-transfected in SH-SY5Y cells with the GLB1 (galactosidase beta 1) reporter gene (in order to normalize 
transfection efficiencies) and either empty vector (Ev, black bars) or Xbp1s (gray bars) cDNAs. Twenty-four hours after transfection, luciferase activity was measured 
(N = 12, analyzed by One-way ANOVA, Tukey’s multiple comparisons test) then expressions of XBP1s and ACTB were analyzed as described in Methods. Data are 
expressed as percent of control Ev/GLB1-transfected cells (taken as 100%) and are the means ± SEM of 4 independent experiments performed in triplicates. (K) The 
scheme (left panel) represents the PINK1 promoter construct (P2.0∆) lacking the −1024/-1021 Xbp1s-responsive element. P2.0 and P2.0∆ promoter constructs were 
co-transfected with the GLB1 reporter gene and either empty vector (Ev, black bars) or Xbp1s (gray bars) cDNAs in SH-SY5Y cells. Twenty-four hours after transfection, 
luciferase activity was measured (N = 9, analyzed by One-way ANOVA, Tukey’s multiple comparisons test) then expression of XBP1s and ACTB were analyzed as 
described in Methods (right panel). Data are expressed as percent of control Ev/GLB1-transfected cells (taken as 100%) and are the means ± SEM of 3 independent 
experiments performed in triplicates. Statistical significances are: **, P < 0.01, ****, P < 0.0001 and ns for non-significant. (L) EMSA analysis of the physical interaction 
of purified recombinant XBP1s and Pink1 biotinylated probes encompassing the −1024/-1021 sequence of the mouse promoter (see panel K) in absence (lane 2) or in 
the presence (lane 3) of an excess of unlabeled probe. Lane 1 corresponds to biotinylated probe alone.
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Figure 2. Xbp1s overexpression leads to increased mitophagy in SH-SY5Y cells. (A-C) SH-SY5Y cells were transiently transfected with an empty vector (Ev) or Xbp1s cDNA treated 
or not with bafilomycin A1 (Baf, 100 nM) then analyzed by western blot for XBP1s (A, N = 15), LC3-II:LC3-I ratio (A and B, N = 12) and SQSTM1/p62 (A and C, N = 15) protein levels. 
Statistical significances were analyzed by ordinary one-way ANOVA followed by Sidak’s multiple comparison test, * P < 0.05, ** P < 0.01, *** P < 0.001, ****, P < 0.0001. (D-J) SH- 
SY5Y cells were transiently transfected with an empty vector (Ev) or Xbp1s cDNA then analyzed for BECN1 (D and E, N = 9), OPTN (D and F, N = 15), TIMM23 (D and G, N = 12), 
TOMM20 (D and H, N = 9), UB (S65) (D and I, N = 12), PRKN (D and J, N = 12) and TUBB protein levels as described in Methods. (K) SH-SY5Y cells were transiently transfected with an 
empty vector (Ev) or Xbp1s cDNA then mitochondrial membrane potential was measured by cell imaging (upper panel, N = 100 cells, two independent experiments, IF in 
histogram) or flow cytometry (, N = 15, 5 independent experiments, FACS in histogram) by means of TMRM probe as detailed in the Methods. Values are expressed as percent of 
control Ev-transfected cells (taken as 100%) and correspond to the means ± SEM of 2–5 independent experiments. Statistical significances were analyzed by Mann-Whitney test, 
****, P < 0.0001. (L) SH-SY5Y cells were transiently transfected with COX8A-EGFP-mCherry cDNA together with an empty vector (Ev) or Xbp1s cDNAs. Fragmented mitochondria 
visualized by red fluorescence punctate (left panel) were counted as described in Methods. The degree of mitophagy (right panel) was calculated by the increase of number of 
cells harboring red punctae. (M,) CASP3 activity fluorimetric assay was performed as described in Methods. Values are expressed as percent of control Ev-transfected cells (taken as 
100%) and correspond to the means ± SEM of 4 independent experiments performed in triplicates. Statistical significances were analyzed by ordinary one-way ANOVA followed 
by Sidak’s multiple comparison test, ***, P < 0.001, ****, P < 0.0001.
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overexpression in dopaminergic neurons increased the protein 
levels of BECN1 (Figure 2D, E), OPTN (Figure 2D, F), UB 
(S65) (Figure 2D,Figure2I) and PRKN (Figure 2D, J). 
Conversely, Xbp1s overexpression reduced TIMM23 (Figure 
2D, G) and TOMM20 (Figure 2D, H) protein expressions. 
Furthermore, we measured the mitochondrial membrane 
potential in living cells using Tetramethyl rhodamine methy-
lester (TMRM) probe and quantified fluorescence signal by 
confocal imaging (Figure 2K, upper panel and IF in histogram) 
and fluorescence-activated cell sorting (FACS) (Figure 2K, 
FACS in histogram). We showed that Xbp1s overexpression 
prevented the disruption of mitochondrial membrane potential 
(Figure 2K) indicating that XBP1s controlled PINK1-mediated 
basal mitophagy. In order to analyze the impact of XBP1s on 
mitophagic flux in living cells, we used COX8A (cytochrome 
c oxidase subunit 8A)-EGFP (enhanced green fluorescent pro-
tein)-mCherry mitophagy reporter [35]. The degree of mito-
phagy was calculated by the increase of the number of cells 
harboring red fragmented mitochondria (engulfed in the lyso-
somal acidic compartment) (Figure 2L). Importantly, this data 
clearly indicated that Xbp1s transfection increased mitophagic 
flux corroborating the LC3-II:LC3-I and SQSTM1 biochemical 
data. Thus, XBP1s expression exacerbated a punctate COX8A- 
linked red fluorescence corresponding to fragmented mito-
chondria, clearance in the lysosomal compartment (Figure 
2L). Of importance, transient overexpression of Xbp1s in pri-
mary cultured neurons fully reproduced the phenotypes 
observed above for Xbp1s overexpression in dopaminergic 
cells (Fig. S6A and S6L). Finally, Xbp1s overexpression 
(Figure 2M, lower panel) allowed us delineating a protective 
phenotype illustrated by a reduction of basal and TP-mediated 
activation of the pro-apoptotic protein CASP3 (caspase 3; 
Figure 2M, histogram).
We performed similar extensive analysis of autophagic/ 
mitophagic reporters in XBP1 KD dopaminergic cells (Figure 
3). First, in basal conditions, we observed decreased LC3-II: 
LC3-I ratios (Figure 3A, B) and augmented SQSTM1 expres-
sion (Figure 3A, C) associated with XBP1 knockdown. Of note, 
baf treatment time-dependently increased both basal and XBP1 
KD -linked LC3-II:LC3-I ratios (Figure 3A, B) and SQSTM1 
expressions (Figure 3A, C), confirming our previous conclusion 
(see Figure 2) that XBP1s controlled mitophagy flux at endo-
genous levels. Furthermore, we observed decreased expressions 
of BECN1 (Figure 3D, E), OPTN (Figure 3D, F), CALCOCO2 
(Figure 3D, G), UB (S65) (Figure 3D, K) and PRKN (Figure 
3D, L) while TIMM23 (Figure 3D, H), TOMM20 (Figure 3D, I) 
and HSPD1 (Figure 3D, J) levels were augmented. Of note, all 
above-described protein markers varied in a perfect opposite 
manner in Xbp1s-overexpressing dopaminergic cells (Figure 
2A–J) and primary cultured neurons (Fig. S6A-K) compared 
to XBP1 KD (Figure 3A–L) cells. Further, opposite to over-
expression of Xbp1s, reduction of endogenous levels of XBP1s 
also drastically reduced mitochondrial membrane potential 
(Figure 3M) and increased basal and TP-stimulated CASP3 
activity (Figure 3N). The latter observation was corroborated 
by our observation of an activation of the apoptotic UPR 
illustrated by the increase of DDIT3 protein and mRNA levels 
(data not shown). Overall, the above data concurred to 
conclude that XBP1s modulated mitochondrial function and 
mitophagy.
XBP1s-induced modulation of mitophagy and 
mitochondrial health is dependent on PINK1
Our data indicated that XBP1s-associated effects on mito-
chondrial and mitophagic processes strictly resembled those 
described for PINK1-associated phenotypes. Although we 
showed that XBP1s was a transcriptional activator of PINK1, 
it remained to definitely establish whether XBP1s-induced 
phenotype was fully or partly dependent on endogenous 
PINK1. To address this question, we have overexpressed 
Xbp1s in PINK1 knockdown (PINK1 KD) dopaminergic cells 
and assessed the influence of PINK1 reduction on the expres-
sion of the above-described panel of mitophagy/autophagy 
protein reporters as well as on the mitochondrial membrane 
potential (Figure 4). First and importantly, comparative ana-
lyses of PINK1 control (PINK1 CT) and PINK1 KD cells 
(compare lanes [-] of black and gray bars in Figure 4B–L) 
indicated that the PINK1 KD-associated mitophagy response 
perfectly mimicked XBP1 KD-induced phenotype (see Figure 
3). Thus, PINK1 KD cells showed decreased levels of BECN1 
(Figure 4A, B), LC3-II:LC3-I ratio (Figure 4A, C), OPTN 
(Figure 4A, E), CALCOCO2 (Figure 4A, F), UB (S65) 
(Figure 4A, 4J) and PRKN (Figure 4A, K) while SQSTM1 
(Figure 4A, D), TIMM23 (Figure 4A, G), TOMM20 (Figure 
4A, H), HSPD1 (Figure 4A, I) and MFN2 (mitofusin 2) levels 
(Figure 4A, L) were increased. Membrane mitochondria 
potential analysis (Figure 4M) also corroborated the protec-
tive role of endogenous PINK1 in the preservation of mito-
chondria function.
Second, in this set of independent experiments, we fully 
reproduced the effects described in Figures 2, 3 and S6 con-
cerning the impact of Xbp1s on the control of mitophagy in 
PINK1 CT cells. Thus, Xbp1s overexpression (compare black 
bars, lanes [-] and [+]) triggered an upregulation of BECN1 
(Figure 4A, B), LC3-II:LC3-I ratio (Figure 4A, C), OPTN 
(Figure 4A, E), CALCOCO2 (Figure 4A, F), UB (S65) 
(Figure 4A, J) and PKKN (Figure 4A, K) while SQSTM1 
(Figure 4A, D), TIMM23 (Figure 4A, G), TOMM20 (Figure 
4A, H), HSPD1 (Figure 4A, I) and MFN2 (Figure 4A, L) levels 
were decreased. Membrane mitochondria potential analysis 
(Figure 4M) also emphasized the protective function of 
XBP1S in the preservation of mitochondria function.
Finally, of utmost importance, all Xbp1s-linked effects on 
expressions of protein reporters and TMRM were fully abol-
ished by PINK1 depletion (Figure 4A–M, compare [-] and [+] 
gray bars in PINK1 KD cells). Overall, our data clearly 
demonstrated that XBP1s-mediated control of mitochondrial 
physiology and mitophagy was fully PINK1-dependent.
Pharmacological blockade of ERN1 reduces endogenous 
PINK1 expression and mimics PINK1-knockdown- 
associated phenotype in mice
Our study showed that XBP1s was a transcriptional activator 
of PINK1 and that this accounted for all PINK1-dependent 
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Figure 3. Endogenous XBP1s lowers mitophagic response. (A-C) SH-SY5Y cells stably expressing either control (scrambled, SC, black bars) or Xbp1 shRNA (Xbp1KD, 
gray bars) were either treated or not with bafilomycin A1 (Baf 100 nM for the indicated times) then examined by western blot (see Methods) for LC3-II:LC3-I ratio (A 
and B, N = 9, one-way ANOVA, Tukey’s multiple comparison test), SQSTM1 (A and C, N = 6, Kruskal Wallis multiple comparison). (D-L) BECN1 (D and E, N = 6, Mann- 
Whitney test), OPTN (D and F, N = 9, Student’s t test), CALCOCO2 (D and G, N = 6, Mann-Whitney test), TIMM23 (D and H, N = 9, Student’s t test), TOMM20 (D and I, 
N = 12, Mann-Whitney test), HSPD1 (D and J, N = 9, Student’s t test), UB (S65) (D and K, N = 9, Student’s t test) and PRKN (D and L, N = 9, Student’s t test) protein 
expressions in SC or XBP1 KD cells. ACTB expressions are provided in (A and D) as controls of protein load. (M) Mitochondrial potentials of SC and XBP1 KD cells were 
analyzed by flow cytometry as described in Methods (N = 15, analyzed by Student’s t test). (N) CASP3 activity expression was measured in basal and TP-stimulated 
conditions as described in Methods (N = 12, analyzed by One-way ANOVA followed by Sidak’s multiple comparison test). (B-N) Data are expressed as percent of SC 
(CT) cells (taken as 100%) and are the means ± SEM of 2–5 experiments performed in triplicates. Statistical significances are * P < 0.05, ** P < 0.01, *** P < 0.001, 
****, P < 0.0001.
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Figure 4. XBP1s-mediated control of mitophagy is fully PINK1-dependent. (A-L) Control (PINK1 CT) or PINK1 knocked-down (PINK1 KD) SH-SY5Y cells were transiently 
transfected with an empty vector (Ev) or with Xbp1s (Xbp1s) cDNA. Twenty-four hours after transfection, BECN1 (A and B, N = 8) LC3-II:LC3-I ratio (A and C, N = 8), 
SQSTM1 (A and D, N = 8), OPTN (A and E, N = 8), CALCOCO2 (A and F, N = 8), TIMM23 (A and G, N = 12), TOMM20 (A and H, N = 12), HSPD1 (A and I, N = 12), UB 
(S65) (A and J, N = 8), PRKN (A and K, N = 8) and MFN2 (A and L, N = 12) protein expressions were analyzed by western blot as described in Methods. ACTB 
expression is provided in (A) as a control of protein load. (M) PINK1 CT and PINK1 KD cells either empty vector (-) or Xbp1s (+) cDNA-transfected were analyzed by 
flow cytometry to measure mitochondrial membrane potential as described in Methods. (B-M) Data are expressed as percent of PINK1 CT non-transfected cells (taken 
as 100%) and are the means ± SEM. of 4–6 independent experiments performed in duplicates. Statistical analyses were performed by Kruskal Wallis multiple 
comparison test (B) and Sidak’s multiple comparisons test (C-M). Statistical significances: ns, not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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XBP1s-mediated control of mitochondrial physiology. Since 
Toy blocks ERN1 and thereby drastically downregulated both 
XBP1s and PINK1 protein and mRNA levels (see Figure 1A, 
B), we postulated that Toy treatment should decrease the 
mitophagy response linked to an XBP1s-mediated PINK1 
downregulation in mouse brain. Figure 5 showed that the 
pharmacological blockade of ERN1 indeed significantly 
reduced PINK1 protein expression (Figure 5A, 5E) as well as 
Xbp1s and Pink1 mRNA levels (Figure 5B, 5C). Moreover, we 
showed that Toy reduced the levels of the mitochondrial DNA 
content marker, D-loop, indicating that XBP1s affected mito-
chondrial function in vivo corroborating our in cellulo TMRM 
data (Figure 5D). Further, Toy reduced BECN1 (Figure 5A, 
5F), LC3-II:LC3-I ratio (Figure 5A, G), OPTN (Figure 5A, 5I) 
and UB (S65) (Figure 5A, K) expressions. Conversely, Toy 
increased SQSTM1 (Figure 5A, H) and TIMM23 (Figure 5A, 
J). Of interest, electronic microscopy analysis showed that Toy 
triggered abnormal mitochondrial morphology, with elon-
gated mitochondria (see arrows in Figure 5M) characterized 
by increased perimeters (Figure 5N) and surface (Figure 5O). 
These results were corroborated by the Toy-induced increase 
in MFN2 (Figure 5A, L) and agreed well with the reduction of 
MFN2 expression observed after Xbp1s overexpression (see 
Figure 4A, L). This data indicated that impairing the upstream 
modulation of the XBP1s-PINK1 signaling by Toy-mediated 
inhibition of the nuclease yielding functional XBP1s, triggered 
mitochondrial defects in vivo similar to those observed in 
both XBP1 KD and PINK1 KD cells. Thus, the XBP1s- 
PINK1 axis also functionally modulated mitochondrial phy-
siology and mitophagy, in vivo.
XBP1s is phosphorylated by PINK1 in cells and in mice 
brain
XBP1s, as is the case for all transcription factors, must shuttle 
to the nucleus to exert its function. It has been demonstrated 
that phosphorylation processes directly impact XBP1s nuclear 
translocation and consequently, its transcriptional function 
[36,37]. Since PINK1 is a well-characterized kinase, we ques-
tioned whether PINK1 could phosphorylate XBP1s, thereby 
unraveling a functional forward loop between XBP1s and 
PINK1. We first compared the ability of wild-type (WT) 
PINK1 and its kinase-dead homolog (MT, PINK1K219M) [38] 
to modulate expressions of phosphorylated forms of XBP1s. 
We examined the status of XBP1s phosphorylation at its 
threonine 48 (XBP1s [p-T48A]) and serine 61 XBP1s 
[p-S61A] that have been proposed as key XBP1s residues 
undergoing phosphorylation [36,37]. In basal (CT) condi-
tions, WT PINK1 enhanced both XBP1s [p-T48A] and 
XBP1s [p-S61A] expressions while the PINK1 mutation abol-
ished this effect (Figure 6A–C, compare black bars). As 
expected, in TP-treated Ev condition, XBP1s [p-T48A] and 
XBP1s [p-S61A] expressions were increased and further 
enhanced by WT PINK1 but not by PINK1 MT (Figure 6A– 
C). In agreement, PINK1 KD cells mimicked the phenotype of 
PINK1 MT-expressing cells. Thus, a drastic reduction of 
XBP1s [p-T48A] and XBP1s [p-S61A] expressions was 
observed in PINK1 KD cells in both basal and TP-linked 
stress conditions (Figure 6D–F). This conclusion was 
supported by the time-dependent reduction of TP-induced 
phosphorylation of XBP1s in MEF cells invalidated for 
Pink1 (pink1−/-) (Fig. S7A). Indeed, nearly all TP-induced 
phosphorylations observed after 8 h of treatment were abol-
ished by Pink1 depletion (Fig. S7A-C). Importantly, brain 
samples from 6–10-month-old pink1−/- mice displayed 
reduced expressions of p-XBP1s (T48) (Figure 6G, H) and 
p-XBP1s (S61) (Figure 6G, I) indicating that XBP1s phos-
phorylation by PINK1 also occurred in vivo. Interestingly, 
the phosphorylation of XBP1s by PINK1 appeared to be age- 
dependent since brain samples from younger pink1−/- mice 
(2–4 months) displayed lower XBP1s [p-T48A]-expression 
(Fig. S7D) while XBP1s [p-S61A] was not detectable at this 
age (not shown).
PINK1 phosphorylates XBP1s in vitro and governs its 
cellular localization
In order to demonstrate direct phosphorylation of XBP1s 
by PINK1, we carried out in vitro phosphorylation assays. 
We first validated this in vitro assay by showing that, 
indeed, ubiquitin (UB), a canonical substrate of PINK1 
[39], underwent phosphorylation by WT PINK1 but not 
by PINK1 MT at its expected serine 65 residue (see UB 
[S65] in Figure 7A). This set of data also showed that WT 
PINK1 but not kinase-dead PINK1 phosphorylated XBP1s 
at the threonine 48. Of note, WT PINK1 did not phosphor-
ylate XBP1s at serine 61 in vitro, indicating that the mod-
ulation of phospho-serine 61 levels observed in cells, aged 
mice brain (Figure 6 and S7) and PD-affected brains (see 
below Figure 8) could be time-dependent or would likely 
require co-factors occurring at late stage of the disease. 
Overall, our data demonstrated that XBP1s was a direct 
substrate of PINK1 and that its phosphorylation occurred 
in cells and mouse brains.
As stated above, we assumed that XBP1s phosphoryla-
tion should modify its cellular localization and likely 
enhance its nuclear load. Thus, we examined the influence 
of wild-type and mutated PINK1 overexpression on XBP1s 
expression in total cell lysates as well as in nuclear and 
cytosolic compartments. In TP conditions, WT PINK1 but 
not PINK1 MT cDNA transfection enhanced XBP1s expres-
sion in total lysate (Figure 7B). In TP-treated empty vector- 
transfected cells, (TP, Ev), as expected, XBP1s was essen-
tially in the nucleus with little if any expression in the 
cytosol (Figure 7B). WT PINK1 expression drastically 
enhanced XBP1s nuclear levels, a phenotype totally pre-
vented by PINK1 mutation (Figure 7B, C). Conversely, 
PINK1 MT allowed unraveling a cytosolic XBP1s compo-
nent that was totally lacking in WT PINK1 expressing cells 
(Figure 7B).
XBP1s mutations on threonine 48 and serine 61 abolish 
XBP1s-mediated control of PINK1 and prevent 
XBP1s-linked modulation of autophagic/mitophagic 
protein reporters
We aimed at assessing whether XBP1s phosphorylation by 
PINK1 reflects a functional forward loop by which PINK1 
AUTOPHAGY 9
Figure 5. Pharmacological blockade of XBP1s impacts mitophagy, mitochondrial morphology and mtDNA in mice brain. (A) Two-month-old mice were intraper-
itoneally injected with toyocamycin (Toy) or vehicle (CT) as described in Methods. Seventy-two hours after injection, Xbp1s (B), Pink1 (C) and Dloop (D) mRNA were 
analyzed by RT-PCR as described in Methods. PINK1 (A and E), BECN1 (A and F), LC3-II:LC3-I ratio (A and G), SQSTM1 (A and H), OPTN (A and I), TIMM23 (A and J), UB 
(S65) (A and K), MFN2 (A and L) protein expressions were analyzed by western blot as described in Methods. ACTB expression is provided in (A) as a control of protein 
load. (B-L) Data are expressed as percent of CT vehicle-injected mice brain (taken as 100%) and are the means ± SEM of 9–14 mice for each group. Statistical 
significances were analyzed by Student’s t test and Mann-Whitney test, ** P < 0.01, *** P < 0.001, **** P < 0.0001. (M) Electron microphotographs illustrating 
mitochondrial morphology in brains (cortical region) from CT (upper) and Toy (lower)-injected mice. Red arrows point to mitochondria in two representative images 
of neuronal cell body (N, nucleus). (N and O) Quantification of mitochondria perimeter and area on brain slices from CT and Toy-injected mice. Bars correspond to the 
average mitochondria perimeter (N, µm) and area (O, µm2) counted from 20–30 images of neuronal cell bodies (2 mice for each condition). Data are expressed as 
means ± SEM and statistical significances were analyzed by Mann-Whitney test, **** P < 0.0001.
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could control its own expression. We assumed that if 
PINK1 controlled XBP1s phosphorylation and thereby, its 
own expression via its kinase activity, mutations of the 
above-identified XBP1s phosphorylated residues should 
abolish XBP1s-mediated control of PINK1 expression. It 
was indeed the case since, while as expected, wild-type 
XBP1s enhanced PINK1 protein and mRNA expressions 
as well as promoter transactivation (see above and Figure 
7D–G), non-phosphorylable XBP1s mutants failed to mod-
ulate PINK1 (Figure 7D–G). The fact that PINK1 could 
indeed control XBP1s transcriptional function was further 
supported by the fact that PINK1 depletion fully prevented 
the basal and TP-induced mRNA levels of EDEM1, 
a canonical XBP1s transcriptional target (Figure 7H [40]). 
Of interest, mutations abolishing PINK1-mediated phos-
phorylation of XBP1s impaired the effect of wild-type 
XBP1s (WT) on BECN1, OPTN, TIMM23, TOMM20, UB 
(S65) and PRKN protein expressions (Figure 7I–N). 
Overall, we concluded that XBP1s was a transcriptional 
activator of PINK1, which in turn, phosphorylated XBP1s, 
enhanced its nuclear localization and thereby PINK1 own 
expression and consequently, PINK1-mediated control of 
mitophagic process.
PINK1 and XBP1s [p-T48A] and XBP1s [p-S61A] 
expressions are increased and positively correlated in 
PD-affected brains
Finally, we examined the status of PINK1, XBP1s [p-T48A] 
and XBP1s [p-S61A] and autophagic/mitophagic protein 
reporters in sporadic PD-affected brains. First, pathological 
brains showed increased expression of PINK1 (Figure 8A, B), 
XBP1s [p-S61A] (Figure 8A, 8C) and XBP1s [p-T48A] (Figure 
8A, D) expressions. Of utmost importance, the expression of 
PINK1 positively correlated with both XBP1s [p-S61A] 
(Figure 8J) and XBP1s [p-T48A] (Figure 8K) expressions. 
This could be directly related to the mitochondrial accumula-
tion of PINK1 in the mitochondria (see Fig. S3), which cor-
responds to its localization and functional site. Interestingly, 
PD-affected brains that have enhanced expressions of XBP1s 
and PINK1 displayed alterations in TIMM23, TOMM20, UB 
(S65) and OPTN (Figure 8E–H) reminiscent of those 
observed after overexpression of XBP1s. Moreover, PD- 
affected brains in which exacerbated cell death has been 
described [41] also exhibited enhanced active CASP3 expres-
sion (Figure 8I) indicating induction of the apoptotic phase of 
the UPR.
Importantly, corroborating these postmortem studies in PD 
brains, we aimed at assessing whether such regulation also 
occurred in PD-linked cellular models. Thus, we examined 
the impact of two well-recognized ER stressors linked to PD 
physiopathology, namely 6-hydroxydopamine (6OHDA) (Fig. 
S8A-D) and oligomeric SNCA [13,42–44] (Fig. S8E-I) in 
differentiated SH-SY5Y neuroblastoma cells. We demonstrate 
that 6OHDA triggered an increase of PINK1 (Fig. S8A and 
S8B) and XBP1s (Fig. S8A and S8C) in a dose-dependent 
manner and that the levels of these two proteins were strongly 
and significantly correlated (Fig. S8D, Spearman, test r = 0.74, 
P < 0.0001). Similarly, oligomeric but not monomeric α- 
synuclein increased both PINK1 and XBP1s expressions 
(Fig. S8E-H), in a strongly correlated manner (Fig. S8I). 
Overall, our study showed that our observations are relevant 
of PD pathological process taking place similarly in cells and 
animal models as well as in PD-affected brains.
Discussion
PD is an age-related neurodegenerative disease whose etiology 
is likely multifactorial and whose anatomical stigmata indicate 
an exacerbated ER stress and severe mitochondrial failure 
[1,4]. The molecular mechanisms underlying these dysfunc-
tions, whether they are directly linked and how they occur are 
poorly understood. In this study, we demonstrated for the 
first time a functional molecular interplay between the tran-
scription factor XBP1s and the kinase PINK1, two proteins 
involved in ER-stress response and mitochondrial homeosta-
sis that could be disrupted in PD.
PINK1 is a key serine-threonine kinase [45] that, in conjunc-
tion with the E3-ligase [46] and transcription factor protein 
PRKN [47,48], behaves as an important modulator of mitophagy 
[49]. Our work clearly established that XBP1s upregulates 
PINK1 transcription in a dopaminergic cell line as well as in 
primary cultured cortical neurons. Interestingly, PINK1 tran-
scription could be modulated by EIF2AK3, a protein participat-
ing in another branch of the UPR [50]. Very few studies aimed at 
understanding PINK1 transcriptional regulation have been 
reported. Thus, it has been shown that PINK1 gene transcription 
is regulated by FOXO3 (forkhead box O3), TP53, NFKB1, PRKN 
and GABPA/NRF2 (GA binding protein transcription factor 
subunit alpha) [25,51–54]. Interestingly, it has been shown that 
PINK1 transcription is also repressed by ATF3 (activating tran-
scription factor 3) in lung cells [55] suggesting that PINK1 
transcriptional regulation may be cell type-dependent. 
Interestingly, Li et al have shown that a prolonged treatment 
(24 h) of cortical neurons with TP leads to a reduction of PINK1 
protein [56]. These apparently discrepant data could likely be 
explained by the fact that the modulation of PINK1 protein 
levels is time-dependent and that prolonged treatment with TP 
triggers a decrease of PINK1 expression. In agreement, our TP 
kinetic studies performed in SH-SY5H cells indicated that TP 
induced a bell-shaped regulation of PINK1 that peaked at 8 h 
and returned to control values at 16 h (data not shown). Of note, 
our in vitro and in vivo data showing the upregulation of PINK1 
by XBP1s agreed well with the increased levels of PINK1 
observed in PD human brains (Figure 8 and [57,58]).
The fact that PINK1 promoter is regulated by several tran-
scription factors linked to distinct ER stress pathways led us to 
speculate that XBP1s could directly impact mitochondrial health 
and fate (mitophagy) and that PINK1 could well account for the 
molecular effector bridging these two cellular paradigms. Our 
hypothesis was corroborated by four independent lines of evi-
dence. First Toy, that blocks ERN1-mediated unconventional 
splicing of XBP1 and thereby, prevents the occurrence of func-
tional XBP1s, similarly impacted endogenous XBP1s and PINK1 
expressions and influenced mitophagy markers and effectors 
in vivo. Second, overexpressed and endogenous XBP1s indeed 
modulated autophagy (LC3-II:LC3-I, SQSTM1, BECN1) and 
mitophagy (PRKN, UB [59], TIMM23, TOMM20) markers 
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Figure 6. PINK1 phosphorylates XBP1s on threonine 48 and serine 61 residues in cells and in mice brain. (A-C) SH-SY5Y cells were transiently transfected with an 
empty vector (Ev), V5-tagged WT Pink1 (WT) or kinase-dead Pink1 mutant (Pink1K219M, MT) cDNAs. Twenty-four hours after transfection, cells were treated for 8 h with 
either vehicle (CT, black bars) or thapsigargin (TP, 1 µM, gray bars). (D-F) PINK1 CT and PINK1 KD cells were treated as in A-C with either vehicle (CT, black bars) or 
thapsigargin (TP, 1 µM, gray bars). V5-tagged PINK1 (A), total XBP1s (A and D) and phosphorylated XBP1s (A and D, pXBP1s [p-S61A], pXBP1s [p-T48A]) expressions 
were measured by western blot as described in Methods. (B,C,E,F) Data corresponding to indicated XBP1s phosphorylated species are expressed as percent of 
untreated Ev (B and C, N = 15) or PINK1 CT cells (E and F, N = 12 and 6 respectively) (taken as 100%) and are the means ± SEM of 2–5 independent experiments 
performed in triplicate. Statistical significances were performed by two-way ANOVA, Tukey’s multiple comparisons test, ns, non-significant, * P < 0.05, ** P < 0.01, 
**** P < 0.0001. (G-I) western blot analysis of pXBP1s [p-S61A] and pXBP1s [p-T48A] in Pink1+/+ and pink1−/- mice brain. Bars are the means ± SEM of 8 mice per 
group. Statistical significances were analyzed by Mann-Whitney’s test (H) and Student’s t test (I), ***, p < 0.001; ****, p < 0.0001.
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Figure 7. PINK1-mediated phosphorylation of XBP1s enhances its nuclear translocation, controls its own transcription and mitophagy, a phenotype abolished by non- 
phosphorylable XBP1s mutants. (A) XBP1s and UB (S65) (used as positive control substrate) phosphorylations by recombinant wild-type PINK1 (WT PINK1) or kinase-
dead mutant PINK1 (PINK1D395A) were performed as described in Methods. XBP1s, XBP1s [p-T48A], XBP1s [p-S61A], total UBB (UB-t), UB (S65) and PINK1 protein levels 
were analyzed by western blot. (B) SH-SY5Y cells were transfected with empty vector (Ev), WT PINK1 or PINK1D395A (MT) cDNA. Twenty-four hours after transfection, 
cells were treated for 8 h without (-) or with (+) thapsigargin (TP, 1 µM). XBP1s, V5-tagged PINK1 and ACTB protein expressions were monitored in whole cell lysate 
(Lys. Tot.) while XBP1s, histone (H2AZ1) and ACTB protein expressions were monitored by western blot in either cytoplasmic (Cyt.) or nuclear (Nuc.) cellular fractions 
prepared as described in Methods. (C) Data corresponding to nuclear XBP1s are expressed as percent of Ev-untreated cells (taken as 100%) and are the means ± SEM 
of 2 independent experiments performed in triplicate. Statistical significances were analyzed by one-way ANOVA, Tukey’s multiple comparisons test * P < 0.05, ** 
P < 0.01, **** P < 0.0001. (D-G) SH-SY5Y were transiently transfected with an empty vector (Ev), wild-type Xbp1s (WT) or Xbp1s mutants (Xbp1s [p-S61A] (S), Xbp1s 
[p-T48A] [T] or Xbp1s [p-S61A]/Xbp1s [p-T48A] [S/T]) cDNAs. Twenty-four hours after transfection, PINK1 protein expressions (D and E, N = 12), promoter activity (F, 
N = 12), and mRNA levels (G) were analyzed as described in Methods. Data are expressed as percent of control Ev-transfected cells (taken as 100%) and are the 
means ± SEM of 4 independent experiments performed in triplicates. Statistical significances were analyzed by one-way ANOVA, Turkey’s multiple comparisons test, 
ns, non-significant, ** P < 0.01, *** P < 0.01. (H) EDEM1 mRNA was measured in basal (CT) or thapsigargin (TP)-stimulated conditions in wild-type (PINK1 CT, black 
bars) or PINK1 KD SH-SY5Y cells (note that EDEM1 mRNA are totally undetectable in PINK1 KD cells). Data are expressed as percent of control (CT)-untreated cells 
(taken as 100%) and are the mean ± SEM of 4 independent experiments performed in triplicates. Statistical analysis was performed by two-way ANOVA, Sidak’s 
multiple comparison test, * P < 0.05, **** P < 0.0001. (D, I-N) Expressions of BECN1 (D and I), OPTN (D and J), TIMM23 (D and K), TOMM20 (D and L) UB (S65) (D and 
M) and PRKN (D and N) were analyzed by western blotting after Ev-, WT Xbp1s or S, T and S/T Xbp1s-mutants cDNAs transfection as described in Methods. Data are 
expressed as percent of Ev cells (taken as 100%) and are the mean ± SEM of 3 independent experiments performed in triplicates. Statistical analysis were analyzed by 
one-way ANOVA followed by either Kruskal-Wallis multiple comparison test (E,L,M) or Tukey’s multiple comparison (F,G,I-K,N), * P < 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001 and ns = non-significant.
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and effectors. Third, the depletion of endogenous PINK1 fully 
mimicked phenotypic modulations triggered by XBP1s deple-
tion. Fourth, importantly, the XBP1s-mediated alteration of 
mitophagy was fully prevented by PINK1 depletion. Overall, 
this set of data is the first demonstration of direct XBP1s- 
mediated control of mitophagy directly and fully linked to tran-
scriptional activation of PINK1.
We also demonstrated for the first time an XBP1s- 
mediated and PINK1-dependent regulation of the autophagic 
receptors OPTN and CALCOCO2. This indicated that PINK1 
was implicated not only in the recruitment of these receptor 
proteins to mitochondria [34,60], but also in the regulation of 
autophagic receptors that have been linked to PRKN-PINK1 
mitophagy process [34]. This agreed well with a decrease of 
LC3 recruitment by OPTN and CALCOCO2 and by conse-
quence, with a reduction of mitophagy response associated 
with PINK1 depletion. Importantly, we showed that Xbp1s 
cDNA transfection led to an accumulation of the mitochon-
drial pools of PINK1 (Fig. S3) compatible with its down-
stream mitophagic effect in absence of a disruption of 
membrane mitochondrial potential (Figures 2K and 3M). 
These results corroborated several studies showing that 
PINK1 can control basal mitophagy. Thus, Jin et al. [61] 
have demonstrated that the accumulation of PINK1 may be 
independent of disruption of mitochondrial membrane poten-
tial and occurs in response to the ER stress mediated by the 
accumulation of misfolded proteins in the mitochondrial 
matrix. Wang et al showed that PINK1-mediated mitophagy 
may be independent of mitochondrial depolarization and 
instead may be a trigger of mitochondrial hyperpolarization, 
thereby again corroborating our data (Figure 2K) [62]. This 
work shows that primary cultured dopaminergic neurons 
prepared from pink1 knockout mice display a depolarized 
∆ψm and that overexpression of wild-type PINK1 restores 
the hyperpolarized ∆ψm observed in PINK1-null dopaminer-
gic cells. This indicates that PINK1 promotes neuroprotection 
by contributing to maintaining the mitochondrial potential 
corroborating our data showing a correlation between XBP1s- 
mediated PINK1 accumulation and increase of ∆ψm.
The few studies concerning the implication of XBP1s in the 
control of autophagy response have yielded contrasting conclu-
sions. Thus, XBP1s has been shown to upregulate autophagy via 
the modulation of BECN1 transcription and consequently auto-
phagosome formation in endothelial cells [21]. Moreover, Xbp1 
knockdown by siRNA approaches leads to a decrease of LC3-II 
levels in auditory cells [22]. By contrast, XBP1s was also shown to 
repress autophagy. Thus, XBP1s downregulates FOXO1 [63,64], 
a protein that enhances autophagy in human cancer cell lines 
[59,65]. Further, Hetz et al. show that Xbp1 depletion leads to an 
aggravation of experimental amyotrophic lateral sclerosis (ALS) 
due to an enhancement of autophagy in motor neurons [66]. 
Although a few studies have linked XBP1s to autophagy, our 
study gathered, to the best of our knowledge, the first evidence 
that XBP1s could control selective elimination of defective mito-
chondria by mitophagy. It also indicated that XBP1s-mediated 
PINK1 regulation was associated with a protective response in 
cells as illustrated by the lowering of CASP3 activity.
The second important and fully original aspect of our study was 
the demonstration that PINK1, which harbors a kinase activity, 
could control XBP1s transcriptional activity via its phosphoryla-
tion at serine 61 and threonine 48. Thus, PINK1-mediated phos-
phorylation of XBP1s promoted its translocation to the nucleus, 
favored its transcriptional activity and thereby, enhanced PINK1 
own transcription. This molecular dialog that could be seen as 
a forward loop was supported by in vitro phosphorylation assay, 
fractionation studies and functional readout. Furthermore, this 
functional interplay was strengthened by the fact that the expres-
sion of mutated XBP1s proteins that resisted PINK1-mediated 
phosphorylation abolished XBP1s-linked enhancement of 
PINK1 protein and mRNA expressions.
Of note, analysis of XBP1s phosphorylation by PINK1 indi-
cated that it directly phosphorylates XBP1s only at threonine 48 
in vitro as well as in young PINK1 transgenic mice. However, 
PINK1-mediated phosphorylation of XBP1s at both threonine 48 
and serine 61 was abolished in aged pink1 knockout mice. 
Whether these observations related to ontogenic modulation of 
PINK1 or distinct affinities of PINK1 for the two residues 
remained unclear. It is of note that XBP1s activation by phosphor-
ylation by kinases unrelated to PINK1 has been unraveled in 
various pathological contexts. Thus, Lee et al. have demonstrated 
that the MAPK14 (p38 mitogen-activated protein kinase 14) 
directly phosphorylates XBP1s at serine 61 and threonine 48 [36] 
and that the resulting activation of XBP1s can contribute to the 
maintenance of glucose homeostasis in obesity. Interestingly, cor-
roborating our data and further supporting the impact of XBP1s 
phosphorylation for PD pathology, Jiao et al. have demonstrated 
that 1-methyl-4-phenyl pyridinium (MPP+), a neurotoxin used to 
mimic PD in vivo, leads to increased phosphorylation of XBP1s at 
serine 61 by CDK5 (cyclin dependent kinase 5) [37]. Most PINK1 
substrates identified to date are either mitochondrial (TRAP1 
[TNF receptor associated protein 1], HTRA2 [HtrA serine pepti-
dase 2]) or recruited to mitochondria (PRKN, UBB) [39,67–69]. 
Interestingly, XBP1s was the first PINK1 substrate directly linked 
to the ER and the UPR response.
Three independent lines of data indicated that the functional 
interplay governing XBP1s-PINK1 cellular homeostasis could 
well be disrupted in Parkinson disease. First, both PINK1 and 
phosphorylated XBP1s protein levels are upregulated in human 
PD brains (see Figure 8A). Second, importantly, we established 
that PD-affected brains displayed enhanced XBP1s phosphory-
lated species at residues reminiscent of those (threonine 48 and 
serine 61) modulated by PINK1 (Figure 8A, C, D). Third, two 
widely used inducers of PD-like pathology, namely 6-hydroxy-
dopamine and oligomeric but not monomeric SNCA increased 
both PINK1 and XBP1s expressions in differentiated dopami-
nergic cells and that their expressions were highly correlated 
(Fig. S8)
Of utmost importance, our data also indicated a strong posi-
tive correlation between PINK1 and these two XBP1s phos-
phorylated species present in control and PD-affected brains 
(see Figure 8J, K). Previous works have shown that the protein 
levels of PINK1 are increased in sporadic PD [57,58] but our 
study was the first to document an increased expression of 
XBP1s in PD-affected brains, and more particularly of its phos-
phorylated forms. This had to be considered in light of previous 
studies showing an enhancement of phosphorylated ERN1 levels 
in several neurodegenerative disorders [70]. Thus, our study 
showed that, indeed, the ERN1-XBP1 branch was upregulated 
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Figure 8. PINK1, XBP1s phosphorylation and mitophagic markers expressions are altered in sporadic Parkinson disease (PD)-affected brains. (A-J) PINK1 (A and B), 
XBP1s [p-S61A] (A and C), XBP1s [p-T48A] (A and D), TIMM23 (A and E), TOMM20 (A and F), UB (S65) (A and G), OPTN (A and H) and CASP3 (A and I) protein 
expressions in control (CT, N = 10) and PD, (N = 8) brains were analyzed by western blot as described in the Methods. Data are expressed as percent of CT brains 
(taken as 100%). Statistical significances were analyzed by Student’s t test: ns, non-significant, ** P < 0.01, *** P < 0.001. Correlations analyses of PINK1 and XBP1s 
[p-S61A] (J) and XBP1s [p-T48A] (K) protein expressions are illustrated in (J and K). PINK1 full gel illustrating the migration profile of full-length PINK1 in control 
(PINK1 CT) and shRNA-depleted PINK1 (PINK1 KD) samples is provided in (A). A representative ACTB gel is provided to illustrate equal protein load.
AUTOPHAGY 15
in PD. Considering that MAPK14 and CDK5 kinases are 
affected in PD [71,72], it remains to be established if they 
independently or coordinately interact functionally with PINK1 
to modulate XBP1s in PD. It should be noted that we have 
previously shown that nuclear TP53, a tumor suppressor that 
also controls autophagy [73], acts as a transcriptional repressor 
of PINK1 [52]. Further, we have established that TP53 also 
downregulates XBP1s expression [24]. Thus, these data fully 
agree with the present study and indicate that TP53 can repress 
autophagy by direct transcriptional repression of PINK1 or 
indirectly, via the downregulation of XBP1s.
XBP1s elicited a pro-mitophagic response. This positive 
regulation agreed with the beneficial role of autophagy/mito-
phagy in physiological conditions or non-chronic stress condi-
tions [74]. The protective role of autophagy was supported by 
the fact that the depletion of the key autophagy proteins ATG5 
or ATG7 in vivo resulted in increased neurodegeneration and 
the presence of cytoplasmic inclusion bodies mainly composed 
of protein aggregates [75,76]. That said, the observation of an 
activation of an XBP1s-PINK1 axis and the delineated forward 
loop questioned whether this corresponded to a protective 
mechanism or if it accounted for ER-stress and mitochondrial 
defects observed in PD. Since XBP1s phosphorylation 
enhanced its nuclear localization and thus, its function, it 
could be envisioned that PINK1-induced phosphorylation of 
XBP1s is beneficial. This could be a transient adaptive response 
that does not last enough to circumvent chronic disease estab-
lishment. The transient expression and protective effect of 
XBP1s has been documented in another neurodegenerative 
disease, namely Alzheimer disease. Thus, we have shown that 
in AD-affected brains and AD animal models, XBP1s expres-
sion is transiently enhanced at early stages of the pathology and 
that this protects against Aβ oligomers-mediated EPHB2 (EPH 
receptor B2)-linked toxicity [77]. In the same line of reasoning, 
we have shown that Aβ oligomers enhance XBP1s levels lead-
ing to a decrease of BACE1 (beta secretase 1) activity, the 
enzyme responsible for Aβ production [78] as a protective 
response [79]. Thus, the protective response elicited by XBP1s 
is probably sufficient to delay the onset and even the progres-
sion of several neurodegenerative disorders including 
Alzheimer and Parkinson diseases at initial stages, but may 
become inefficient considering their chronic, long-lasting nat-
ure. According to this statement, it is worth noting that both 
the UPR and autophagy processes are characterized by an 
adaptation and an apoptotic phase [74,80]. Thus, one can 
envision that, even if the beneficial transient activation of the 
XBP1s-PINK1 axis occurs, the chronic activation of both UPR 
and autophagy responses may lead to the firing of apoptotic 
stigmata that characterize neurodegenerative diseases. 
Interestingly, we documented in this study a correlation 
between the XBP1s-PINK1 interplay and activation of apopto-
tic response (illustrated by CASP3 activation) in sporadic PD- 
affected brains suggesting that the protective effects are 
mediated by the interplay PINK1-XBP1s had been overcome 
by the sustained PINK1-mediated mitophagy response at late 
stage of the disease.
Overall, our work is the first demonstration of a link 
between the UPR and mitophagy responses via a functional 
crosstalk between XBP1s and PINK1 and that this physiolo-
gical signaling cascade may be disrupted in PD conditions.
Materials and methods
Constructs description and transfection approaches
The mouse Xbp1s-Flag pcDNA3 has been designed by one of us 
and described in [81]. The XBP1 shRNA and scramble (SC) 
shRNA sequences have been cloned in the FUGW lentiviral vector 
(Addgene, 14883 [82]). The human PINK1 and mouse Pink1 
promoters have been described in [51]. The pGL3 vector 
(Promega, U47295) containing the mouse Pink1 promoter served 
as a template to generate the promoter deleted of the 5′-CGAG-3′ 
nucleotides. This deleted motif constitutes part of the XBP1s 
putative binding site. This sequence is located from nucleotides 
−1026 to −1021 upstream of Pink1 ATG start codon. The primers 
used were forward: 5ʹ- 
GTGGATTTCTGAGTTGCCAGCCTGGTCTAC-3ʹ and reverse 
5ʹ-GTAGACCAGGCTGGCAA CTCAGAAATCCAC-3ʹ. The 
generation of wild-type (WT PINK1) and mutant PINK1K219 V5- 
tagged of human PINK1 coding sequence in the mammalian 
expression vector pcDNA6 (Invitrogen, V220-20) has been 
described [38] and graciously provided by Dr. St Georges Hyslop 
(Tanz Center for Research in Neurodegenerative Diseases, 
Toronto, Canada). Wild-type and mutated Xbp1s coding 
sequences in pcDNA3.1 vector (mutants: Xbp1s [p-T48A], Xbp1s 
[p-S61A] and Xbp1s [p-T48A/S61A]) have been described [36]. 
Oligonucleotides containing an shRNA targeting human PINK1 
(primer forward: 5ʹ- 
GATCCCCCCAAGCTGGTCTAGTAGATTTCAAGAGAATC-
TACTAGACCAGCTTGGTTTTTA-3ʹ and reverse: 5ʹ- 
AGCTTAAAAACCAAGCTGGTCTAGTAGATTCTCTTGAA-
ATCTACTAG ACCAGCTTGGGGG-3ʹ) or a scrambled RNA 
(primer forward: 5ʹ-GATCCCCGAGTTACCCGC 
TAGATGTATTCAAGAGATACATCTAGCGGGTAACTCTT-
TTTA-3ʹ and reverse: 5ʹ- 
AGCTTAAAAAGAGTTACCCGCTAGATGTATCTCTTGAA-
TACATCTAGCGGGTAACTCGGG-3ʹ) have been inserted in 
the pSUPER.neo+GFP (green fluorescent protein) vector accord-
ing to the manufacturer’s instructions (Oligoengine, VEC-PBS 
-0006). All the constructs were verified by sequencing. Transient 
and stable transfections of SH-SY5Y (ATCC®, CRL-2266™) were 
carried by means of Lipofectamine 2000 (Invitrogen, 11668019) 
according to the manufacturer’s instructions.
Lentivirus production and SH-SY5Y cells infection
shRNA lentivirus production was performed as described in [77]. 
In brief, XBP1 depletion was performed by means of validated 
shRNA sequences targeting human and mouse XBP1 under the 
RNU6 promoter. Target sequence was 5′- 
GGTCTGCTGAGTCCGCAGCA-3ʹ [24,83]. The RNU6-shRNA 
expression cassette (pSilencer 2.1-U6 Neo; Ambion, Thermo Fisher 
Scientific, AM5764) was inserted in the PacI site of a modified 
FUGW lentiviral backbone, placing the shRNA cassette upstream 
of a UBC (ubiquitin C) promoter directing expression of enhanced 
GFP. A similar construct expressing a scrambled scRNA (5′- 
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GCCCGTCTGCGTGGAGCTAA-3′) was used as a control. Viral 
titers were determined by p24 ELISA (Cell Biolabs, VPK-107). 
Concentrated lentiviruses (scramble RNA XBP1 = 3.39 x 1010 
Lentiviral Particles [LPS]/ml, shRNA XBP1 = 3.08 x 1010 LPS/ml) 
were directly added to SH-SY5Y cells. Four days after infection, 
cells were re-plated in 100 mm diameter dishes in order to generate 
enough cells for either conservation at −150°C or analysis of the 
percentage of protein and mRNA XBP1s depletion in basal and TP 
conditions by western blot and real-time quantitative PCR analy-
sis, respectively (see below).
Electrophoretic mobility gel shift assay (EMSA)
We performed EMSA by means of a commercial gel shift 
chemiluminescent EMSA assay kit (Promega, E3050). In 
brief, purified wild-type XBP1s recombinant protein (300 
ng) or control nuclear extracts were pre-incubated in 1X Gel 
Shift Binding buffer (Promega, E3050) at 20°C for 10 min. 
When indicated, an excess (4 pmol) of unlabeled competitor 
oligonucleotides was added. Positive control of the experi-
ment corresponds to a non-related labeled control DNA (20 
fmol) added to the nuclear extract (data not shown). After this 
pre-incubation step, we added when indicated 20 fmol of 
double-stranded 5ʹ biotin end-labeled PINK1-derived oligo-
nucleotides (forward: 5ʹ- 
GGATTTCTGAGTTCGAGGCCAGCCTGGTCT-3ʹ; reverse: 
5ʹ-AGACCAGGCTGGCCTCGAACTCAGAAATCC-3ʹ) con-
taining the delineated -1025-1021 XBP1s responsive element 
and incubated all the reactions at 20°C for 20 min. The 
samples were resolved by electrophoresis on 
a nondenaturing acrylamide gel (5%) at 4°C, transferred to 
a positively charged nylon membrane (Thermo Fisher 
Scientific, 77016), and after cross-linking with an UV-light 
cross-linker (equipped with a 254-nm bulb), revealed by 
means of streptavidin conjugated to horseradish peroxidase 
(HRP; Active Motif, 37341) and a chemiluminescent 
substrate.
Cell models and pharmacological ER-stress modulation
Most of the experiments were performed in non- 
differentiated SH-SY5Y human neuroblastoma cells cultured 
at 37°C and 5% (vol:vol) CO2, in Dulbecco’s Modified Eagle’s 
Medium (DMEM; Gibco-Invitrogen, 41965–039) supplemen-
ted with 10% fetal calf serum (Dutscher, S1900-500) contain-
ing penicillin and streptomycin (100 U/ml; Gibco, 
15140–122). These cells were routinely profiled and validated 
by Short Tandem Repeat profiling according to the manufac-
turer’s instructions (GenePrint® 10 System, Promega) and 
tested for mycoplasma contamination PCR according to 
a previously published paper [84]. When indicated, these 
cells were treated with 1 µM of thapsigargin (Sigma-Aldrich, 
T9033) or 10 µg/ml of tunicamycin (Sigma-Aldrich, T7765) 
for 8 and 6 h respectively. A pre-treatment with 1 µM toyo-
camycin (Sigma-Aldrich, T3580) for 16 h was performed in 
a subset of experiments in which cells were co-treated with 
thapsigargin and toyocamycin. For cell fractionation proce-
dures, these cells were treated with 5 µM of CCCP (Sigma 
Aldrich, C2759) for 6 h. In a subset of experiments, cells were 
treated for 2 or 4 h with baf (100 nM, Enzo Life Sciences, 
BML-CM110-0100).
SH-SY5Y cells stably overexpressing the shRNA targeting 
XBP1 or a control scrambled sequence were obtained by 
transduction approaches. SH-SY5Y cells overexpressing the 
shRNA targeting PINK1 or a control scrambled sequence 
were obtained by transfection approaches.
Mouse embryonic fibroblasts (MEFs) control or invali-
dated for PINK1 were provided by Dr. B. De Strooper (VIB- 
KU Leuven center for brain and disease research, 
Belgium) [85].
SH-SY5Y differentiation and treatments
In the experiments described in Fig. S5G and S8 , we have 
differentiated stable naïve and XBP1-depleted SH-SY5Y neuro-
blastoma cells by means of a subsequent treatment with retinoic 
acid (Sigma-Aldrich, R2625) and 12-O-tetradecanoyl-phorbol 
-13-acetate (TPA, Sigma-Aldrich, P8139) according to an estab-
lished protocol [86]. In brief, SH-SY5Y (2 x 105 cells) were plated 
on 6-well culture plates (Corning Costar, 3516) in normal med-
ium containing DMEM/F12, 10% fetal bovine serum, penicillin- 
streptomycin and sodium pyruvate. Twenty-four hours after 
plating, SH-SY5Y cells were differentiated for 3 d by addition 
of retinoic acid (10 µM) in neurobasal media containing B-27 
(2%) and L-glutamine (1%, Sigma-Aldrich, Milan, Italy), then 
the media were removed and replaced with neurobasal media 
containing TPA (80 nM), B-27 (2%) and L-glutamine (1%) for 
another 3 d. Differentiation state was confirmed by analyzing the 
protein levels of the dopaminergic marker TH (tyrosine- 
hydroxylase) by western blot (antibody referenced in Table 1). 
In a subset of experiments, differentiated SH-SY5Y cells were 
treated for 24 h with either 6-hydroxydopamine (6OHDA; 
Sigma-Aldrich, H4381) at 10, 25 and 50 µM or with SNCA 
monomers or oligomers (2 µM for 8 h). As described previously 
[87], SNCA oligomers were produced by incubating recombi-
nant human SNCA (Anaspec, AS-55555) at 1 mg/ml (70 µM) 
with a 30:1 excess of 4-hydroxy-2-nonenal (HNE; Sigma- 
Aldrich, H9538) overnight at 37°C. After incubation, the reac-
tion was centrifuged by using an Amicon 3-kDa cutoff ultra- 
centrifugal unit (Millipore, UFC500324) for 10 min at 14 000 x g 
to remove unbound aldehyde.
Mouse and human brains description and processing for 
analysis
Brains from pink1 knockout (pink1−/-) male mice have been 
kindly provided by Dr. J. Shen and have been extensively 
described [88]. Control or pink1−/- brains of 2–4 or 6–10- 
month-old were transferred to green bead tubes (MagNA 
Lyser Green beads; Roche, 03358941001) containing 1 ml of 
lysis buffer (10 mM, Tris-HCl, pH 7.5 supplemented with 
a protease inhibitors cocktail [Sigma-Aldrich, P2714], and 
phosphatase inhibitors [1 mM sodium orthovanadate, 5 µM 
sodium fluoride]). Mouse brains were subsequently bead- 
beaten for 45 s at 4,700 x g in a MagNA Lyser instrument 
(Roche). Homogenates were then sonicated on ice before 
western blot analysis.
AUTOPHAGY 17
Human substantia nigra samples were obtained from 
brains collected in a Brain Donation Program of the Brain 
Bank “Neuro-CEB” run by a consortium of patients 
Associations: CSC (cerebellar ataxias), Fondation ARSEP 
(research on multiple sclerosis), France Parkinson, “Vaincre 
Alzheimer Fondation”. The consents were signed by the 
patients themselves or their next of kin in their name, in 
accordance with the French Bioethical Laws. The Brain Bank 
Neuro-CEB (BB-0033-00011) has been declared at the 
Ministry of Higher Education and Research and has received 
approval to distribute samples (agreement AC-2013-1887). 
These samples include 10 controls and 8 PD patients. 
Controls include four amyotrophic lateral sclerosis (ALS) 
patients (control non-PD-associated pathology): 1811 (male, 
55 years-old), 1821 (female, 68 years-old), 1822 (male, 
64 years-old), 1823 (female, 62 years-old), one sample from 
an aged-matched healthy patient 3659 (male, 61 years-old), 
five samples from healthy patients with Alzheimer like lesions: 
8730 (male, 82 years-old), 6283 (female, 83 years-old), 6658 
(female, 93 years-old), 7024 (female, 76 years-old), 7197 
(male, 85 years old). Samples from PD patients include: 
3605 (male, 64 years-old), 4489 (male, 75 years-old), 4513 
(female, 77 years-old), 5193 (male, 75 years-old), and 8460 
(male, 66 years-old), 4291 (female, 72 years-old), 8418 (male, 
82 years-old) and 7743 (male, 72 years-old). The last three 
cases of PD patients have Alzheimer-like lesions. The mean 
postmortem delay was 28.2 ± 15.3 h. The samples were homo-
genized and lysed as done for mice brain samples.
Primary cultured neurons (pharmacology, transfection 
and transduction)
Primary cultures of rat cortical neurons were performed as 
extensively described in [77]. In brief, cortical neurons from 
rat pups (P0) (http://www.criver.com/products-services/basic- 
research/find-a-model/spraguedawley-rat) were obtained after 
trypsin dissociation. Cells were plated in polylysine-coated 
wells and maintained in serum-free neurobasal medium 
(Gibco, 12348–017) supplemented with B27 (Gibco, 
17504044) and antibiotics (Thermo Fisher Scientific, 
15070–063). Half of the medium was changed after 1 d in 
culture. Cells were used after 9 d in culture. Neuronal cultures 
were either submitted to ER stress by pharmacological treat-
ments (see above) or transiently transfected with empty or 
Xbp1s cDNA or with scramble or Xbp1s shRNA expressing 
plasmids with lipofectamine according to manufacturer con-
ditions. After treatment and transfection, cells were harvested 
and frozen at −80°C for subsequent determination of either 
proteins or mRNA levels and analysis of promoter activity.
Western blot (cells and mouse brains)
Mouse brains and cells were resuspended in lysis buffer (10 mM 
Tris-HCl, pH 7.5, containing a protease inhibitors cocktail and 
phosphatase inhibitors (1 mM sodium orthovanadate, 5 µM 
sodium fluoride) and then sonicated before western blot analy-
sis. Expressions of proteins were analyzed with 50 µg of cell lines 
or mouse brain homogenates loaded on 10–12% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
semi-dry transferred for 10 min by means of the ready to use 
transfer kit nitrocellulose (Bio-Rad, 1704271) and the Trans- 
Blot® Turbo™ Transfer System (pre-programmed Bio-Rad pro-
tocol for 2 mini gels of 1.5 mm). Transferred proteins were then 
immunoblotted using the antibodies listed in Table 1. The full 
gels of PINK1 containing migration controls were provided for 
each cell and tissue type (first time appearance) to illustrate 
antibody specificity. Immunological complexes were revealed 
with adequate anti-rabbit or anti-mouse IgG-coupled peroxidase 
antibodies (Jackson ImmunoResearch, 111–036-045) by the 
electrochemiluminescence detection method (Roche 
Diagnostics S.A.S). Chemiluminescence was recorded using 
a luminescence image analyzer LAS-4000 (Raytest, Fuji) and 
quantifications of non-saturated images were performed with 
the FUJI Film Multi Gauge image analyzer software.
Table 1. List of antibodies used in western blot analysis.
ANTIBODIES SPECIES DILUTION Company (catalog #)
PINK1 Rabbit 1: 1000 Abiocode (R3173-2)
XBP1 Rabbit 1: 1000 Santa Cruz Biotechnology Inc. (sc-8015)
LC3 Rabbit 1: 2000 Novus Biologicals (NB100-2220)
SQSTM1/p62 Rabbit 1: 2000 Novus Biologicals (NBP1 – 49956)
OPTN Mouse 1: 1000 Santa Cruz Biotechnology Inc. (sc-166576)
CALCOCO2/NDP52 Mouse 1: 500 Santa Cruz Biotechnology Inc. (sc-376540)
TIMM23 Mouse 1: 1000 BD Biosciences (611222)
TOMM20 Mouse 1: 1000 BD Biosciences (612278)
H2AZ1 Rabbit 1: 1000 GeneTex (GTX10823S)
Phospho-ubiquitin S65 UB (S65) Rabbit 1: 1000 Boston Biochem (A110)
Ubiquitin Rabbit 1: 1000 Novus Biologicals (NB300-129)
PRKN Mouse 1: 2000 Merck Millipore (MAB5512)
MFN2 Mouse 1: 1000 Abcam (ab56889)
HSPD1/HSP60 Mouse 1: 1000 Santa Cruz Biotechnology Inc. (sc-59567)
XBP1s [p-S61A] Rabbit 1: 10 000 U.Ozcan
XBP1s [p-T48A] Rabbit 1: 10 000 U.Ozcan
GAPDH Mouse 1: 5000 EMD Millipore (MAB374)
ACTB/actin Mouse 1: 5000 Sigma-Aldrich (A5316)
TUBB/tubulin Mouse 1:2000 Sigma-Aldrich (T5168)
TH (tyrosine hydroxylase) Rabbit 1: 1000 GeneTex (GTX113016)
SNCA Mouse 1: 1000 BD Biosciences (610787)
BECN1 Rabbit 1: 1000 Enzo Life Sciences (ADI-905-721-100)
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mRNA analysis (cells and mouse brains)
RNA from cells and mouse brains (one hemisphere per mouse 
was stabilized in RNAlater [RNA stabilization reagent] Qiagen, 
76104) were extracted and treated with DNAse using RNeasy or 
RNeasy Plus Universal mini kits respectively following manu-
facturer’s instructions (Qiagen, 74106 and 73404, respectively). 
Two µg of total RNA were reverse transcribed (GoScript Reverse 
Transcriptase; Promega, A5002) using oligo-dT priming then 
samples were subjected to real-time PCR by means of a Rotor- 
Gene 6000 apparatus (Qiagen), using the SYBR Green detection 
protocol (Roche Life Science). Specific primers (Eurogentec) for 
human, mouse and rat PINK1/Pink1, XBP1s/Xbp1s and house-
keeping genes were designed with the Universal Probe Library 
Assay Design Center software (Roche Applied Science) and are 
listed in Table S1.
Promoter activity
Mouse/human full-length and 5′ end-truncated Pink1/PINK1 
promoter-luciferase constructs have been previously described 
[51]. The transcriptional regulation of Pink1/PINK1 promo-
ters was measured after co-transfection of 1 µg of the above 
cDNA and 1 µg of GLB1 (galactosidase beta) cDNA (in order 
to normalize for transfection efficiencies) by means of lucifer-
ase reporter gene and GLB1 kits according to the manufac-
turer’s instructions (Promega). In a subset of experiments, 
1 µg of empty pcDNA3.1 or wild-type Xbp1s cDNA were co- 
transfected with 0.5 µg of GLB1 and 0.5 µg of Pink1 promoter 
cDNAs.
CASP3 activity measurement
SH-SY5Y cells overexpressing or not XBP1s were plated and 
grown in 6-well plates for 24 h and treated for 8 h without or 
with thapsigargin (1 µM). CASP3-like enzymatic activity was 
fluorimetrically recorded on a spectral scanning multimode 
reader (Varioscan, Thermo Fisher Scientific) as described 
in [89].
Mitophagy flux analysis
pCLBW COX8-EGFP-mCherry plasmid was a kind gift from 
David Chan (Addgene, 78520 [35]). Mitophagic flux was 
performed as described in [35]. This probe allows the detec-
tion of mitophagy flux thanks to differences in pKa of 
enhanced green fluorescent protein (EGFP), and mCherry 
protein expressed in tandem with the mitochondrial localiza-
tion signal of COX8. In neutral compartment (pH7) the probe 
fluoresces yellow (merge of green and red signals). During 
mitophagy, fragmented mitochondria are delivered to lyso-
somes where the low pH quenches the EGFP signal. The 
result is that a portion of mitochondria forms punctae struc-
tures and fluorescence is red only. Images of live cells were 
acquired 48 h post-transfection with Zeiss LSM 780 and 63X 
objective. The quantification was performed on different 
fields of view obtained in three independent experiments. 
Data show the percentage of cells undergoing mitophagy. 
A threshold of a single or more red-alone punctae per cell 
was applied to all cells expressing human COX8-EGFP- 
mCherry probe.
Mitochondrial potential disruption analysis
Mitochondrial membrane potential (Δψm) was accessed using 
live imaging analysis of TMRM probe, a fluorescent cation 
that distributes into the mitochondrial matrix of active mito-
chondria following the electrochemical gradient as detailed in 
[25]. Cells spotted on 25 mm cover slips were loaded with 
10 nM TMRM in cell culture medium at 37°C for 30 min. 
Images were acquired (excitation: 559 nm, emission: 
575–675 nm) on a LEICA TCS SP5 confocal microscope 
(Leica Microsystems) at 37°C. To obtain normalized TMRM 
fluorescence signal, Z-stack images were acquired before and 
after application of the mitochondrial uncoupler carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 
5 mM, Sigma- Aldrich, C2920). To demonstrate specific 
TMRM binding, measurements were corrected for residual 
TMRM fluorescence after full Δψm collapse with FCCP [90]. 
TMRM intensity was quantified on Z-stack maximal projec-
tion images after thresholding, using ImageJ software (NIH) 
[91]. The TMRM signal was also analyzed using the 
NovocyteTM flow cytometer (ACEA Biosciences Inc.). 
TMRM was excited with the 543 nm laser line, and emission 
was performed at 600 ± 10 nm. SH-SY5Y neuroblastoma cells 
and primary cultured neurons were loaded for 30 min at 37°C 
with TMRM (5 nM). TMRM fluorescence from 10,000 cells 
was acquired and the median value was obtained using the 
NovoExpressTM software (ACEA Biosciences Inc.). Cellular 
gating was set the same way in all measurements. 
Unstained- and FCCP-treated cells were used as controls.
Phosphorylation in vitro
XBP1s phosphorylation by PINK1 was analyzed as described 
[92]. In brief, recombinant XBP1s (1 µg) and ubiquitin (posi-
tive control, Boston Biochem, U100H, 1 µg) were incubated 
with recombinant WT PINK1 or PINK1D359A (Ubiquigent, 
66–0043-050 and 66–0044-050 respectively, 1 µg) in a final 
volume of 20 µL of kinase assay buffer (20 mM HEPES 
[Sigma-Aldrich, H3375], pH 7.4, 10 mM dithiothreitol 
[DTT, Sigma Aldrich, 20–265], 0.1 mM EGTA [Sigma- 
Aldrich, E4378], 10 mM MgCl2, 1 mM ATP) for 2 h at 37° 
C. The reactions were terminated by addition of 5X SDS 
(Sigma-Aldrich, L3771) loading buffer (375 mM Tris, pH 
6.8, 9% [w:v] SDS, 50% [v:v] glycerol [Prolabo 
VWR,24388.295] 9% [v:v] beta-mercaptoethanol [Sigma- 
Aldrich, M3148], 0.03% (w:v) bromophenol blue [SERVA, 
15375]), incubated for 15 min at 56°C to prevent spontaneous 
ubiquitin dimers formation, then 200 ng of proteins were 
analyzed by western blot using phospho-specific XBP1s and 
ubiquitin antibodies as described in Table 1.
Cell fractionation
Cells were harvested, pelleted by centrifugation at 1,000 x g 
for 3 min at 4°C, lysed in 300 µl of homogenization buffer 
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(20 mM HEPES pH 7.4, 1.5 mM MgCl2, 1 mM EDTA, 1 mM 
EGTA, 1 mM DTT, protease inhibitors cocktail) and homo-
genized with a syringe (Agani Terumo 26 G needles). 
Homogenates were left in ice during 15 min then centrifuged 
at 850 x g for 5 min at 4°C in order to recover the nuclear 
fraction (pellet). Pellets were homogenized in RIPA buffer 
(50 mM Tris pH 7.4 containing 150 mM NaCl, 1 mM 
EDTA, 1% Triton X-100 [Sigma-Aldrich, X100], 0.5% deox-
ycholate [Sigma-Aldrich, D6750], 0.1% SDS complemented 
with a cocktail of protease inhibitors) then sonicated twice 
for 15 s on ice. Supernatant was centrifuged at 20,000 x g for 
1 h 30 min at 4°C to obtain the cytosolic fraction. Both 
nuclear and cytosolic fractions were submitted to western 
blot analysis. To isolate a crude mitochondrial fraction from 
cultured cells (one 6-well plate per condition), we removed 
the media, washed cells once with PBS, added 1 mL per well 
of 1X PBS (Euromedex, ET330-A), 5 mM EDTA. Detached 
cells were pelleted by centrifugation at 1,000 x g for 3 min at 
4°C. After rinsing in PBS, another centrifugation was per-
formed then pellets were resuspended and incubated for 
15 min in isotonic buffer (250 mM mannitol [Sigma- 
Aldrich, M9647], 5 mM HEPES, 500 µM EGTA, 0.01 g BSA 
[Sigma-Aldrich, A9647]) supplemented with a protease inhi-
bitors cocktail in ice. Swollen cells were manually disrupted 
with a Dounce homogenizer (hundred up and downs). Lysates 
were centrifuged at 1,000 x g for 5 min at 4°C. Supernatants 
were collected and centrifugated again at 1,000 x g for 5 min 
at 4°C. Supernatants were carefully collected and submitted to 
centrifugation for 10 min at 8000 x g at 4°C. The supernatants 
(containing the cytosolic fraction, plasma membrane, lyso-
somes and microsomes) and the mitochondrial pellets resus-
pended in 35 µL of isotonic buffer were both kept for further 
western blots analyses.
Electron microscopy
Electronic microscopy was performed as previously described 
[93]. In brief, mice treated with toyocamycin or its vehicle 
received a lethal dose of a combination of ketamine (120 mg/ 
kg) and xylasine (24 mg/kg) and transcardially perfused with 
ice-cold physiological saline followed by 2.5% glutaraldehyde, 
0.1 M cacodylate buffer, pH 7.4. Brains were sliced (200 μm) 
on a vibratome and 2 mm cubes from the cortices were 
microdissected under binoculars and post-fixed in osmium 
tetroxide (1% in 0.1 M cacodylate buffer). The tissues were 
embedded in EPON resin (EMS, 14120) and 70 nm ultrathin 
sections were contrasted with uranyl acetate and lead citrate 
and visualized using a JEM 1400 electron microscope operat-
ing at 100 kV equipped with a Morada SIS camera. We 
analyzed mitochondrial area and perimeter by the software 
Image J (http://rsb.info.nih.gov/ij/).
In vivo studies
Wild-type mice purchased from Charles River were housed 
with a 12:12 h light/dark cycle and were given free access to 
food and water. All experimental procedures were in accor-
dance with the European Communities Council Directive of 
24 November 1986 (86/609/EEC) and local French legislation. 
Adult wild-type males (C57BL6) aged 2 months were used. 
Mice were intraperitoneally injected with either vehicle 
(0.03% DMSO, 0.02 M Na2HPO4, pH 7.4 buffer containing 
150 mM dextrose [Sigma-Aldrich, D9434]) or tunicamycin 
(1 mg/kg; Merck, 504570) dissolved in the same vehicle [94]. 
Mice were intraperitoneally injected with either vehicle 
(0.0125% DMSO, 0.02 M Na2HPO4 buffer containing 
150 mM dextrose) or toyocamycin (1 mg/kg) dissolved in 
the same vehicle [26]. Animals were sacrificed 72 h after 
injection. Mice brains were recovered and one hemisphere 
was immediately frozen for ulterior proteins analysis while 
the other was stabilized with RNAlater for mRNA analysis by 
real-time PCR.
Statistical analysis
Statistical analyses were performed with GraphPad Prism soft-
ware (San Diego, California USA). The choice of parametric 
versus non-parametric test was established after assessment of 
the normality test (D’Agostino-Pearse omnibus Normality 
test) to assure Gaussian distribution of values. Two groups 
of variables that have passed the normality test were analyzed 
by unpaired Student’s t-test while two groups of variables that 
have not passed the normality test were analyzed by the 
Mann-Whitney test. Analysis of more than two groups of 
variables that have passed the normality test was performed 
by ordinary One-way ANOVA while analysis of more than 
two groups of variables that have not passed the normality test 
were analyzed by Kruskal-Wallis test. Grouped analysis of one 
or more groups was performed by two-way ANOVA followed 
by a Tukey’s multiple comparisons test. Data correlation 
analyses were performed by either Pearson or Sperman tests 
after the evaluation of the Gaussian distribution of values. All 
tests are two-sided; the mean was defined as the center value 
and error bars correspond to SEM. The number of samples, 
replication of experiments and the p values (stars) are pro-
vided in figure legends. Significant differences are: *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001 and ns = non- 
significant.
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